Inozyme
Boston
About Inozyme
Inozyme is a provider of therapies for rare diseases of calcification affecting soft tissues and bone created to offer potentially disease-modifying therapies to help children who are affected with rare, but severe and debilitating disorders of metabolism. The company's enzyme replacement therapy provides the treatment of Generalized Arterial Calcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2), enabling patients to treat diseases characterized by mineral imbalances in the body.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $353.1M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jul 2023)
- Ticker: nasdaq:INZY
- Website: inozyme.com
- Phone: +1 (857) 330-4340
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/inozyme-139142 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.